TRIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trinity Biotech PLC (TRIB) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators suggest a bearish trend, and there are no significant trading signals or strong positive catalysts to justify immediate investment. While the company has shown revenue growth driven by demand for its HIV rapid tests, the financial performance still reflects a net loss, and the stock's price action is weak. It is advisable to monitor the stock for better entry points or stronger positive developments.
The MACD is negative and expanding, indicating bearish momentum. The RSI is neutral at 29.453, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 0.537. Overall, the technical indicators suggest a bearish trend.
The company reported a 43% year-over-year revenue increase in Q1 2026, driven by strong demand for its TrinScreen™ HIV rapid test. Additionally, it secured over 2 million purchase orders for Q3 2026.
The company reported a net loss of $4.39 million in Q1 2026, despite the revenue growth. Technical indicators are bearish, and there is no significant insider, hedge fund, or congress trading activity to suggest strong confidence in the stock.
In Q1 2026, Trinity Biotech reported a net loss of $4.39 million, a 50% reduction from the previous year. Revenue increased by 43% year-over-year to $10.85 million, driven by strong sales of its Rapid HIV tests. However, the company remains unprofitable.
No recent analyst ratings or price target changes are available for TRIB.
